Eagle Pharmaceuticals (EGRX): Raising PT After Surprise News But Ahead Of Analyst Day - RBC

RBC Capital analyst, Randall Stanicky reiterated his Outperform rating on shares of Eagle Pharmaceuticals (NASDAQ: EGRX) and raised his price target to $93 from $80. The analyst was surprised by the CMS decision to reverse the prior J-code decision and enhances a highly visible cash flow base ahead of several other important updates.

Despite the 19% move yesterday, the analyst believes there is continued momentum ahead with focus now on next week's earnings and analyst day.

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $68.10 yesterday.

You May Also Be Interested In

• MarineMax (HZO) PT Lowered to $35 at Stifel
• Merck (MRK) PT Raised to $143 at Truist Securities
• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban